Toshi Ono (Presenter)
Nacalai USA Inc.
Authorship: Ken Tseng¹, Toshi Ono¹, Tsunehisa Hirose²
¹Nacalai USA, Inc., San Diego, United States, ²Nacalai Tesque, Inc., Kyoto, Japan
| Short Abstract In the first part, Δ9-THC, 11-hydroxy-Δ9-THC and 11-nor-9-carboxy-Δ9-THC are detected using a simple gradient. In the second part, four cannabinoids, CBD, CBN, Δ9-THC, and Δ8-THC were baseline separated making quantification easy. |
Long Abstract
Of the roughly 60 cannabinoids, delta-9-tetrahydrocannabinol (Δ9-THC) is the primary psychoactive molecule found in cannabis plants. Δ9-THC and its metabolites have been widely studied. In the first part of this study, Δ9-THC, 11-hydroxy-Δ9-THC and 11-nor-9-carboxy-Δ9-THC are detected using a simple gradient of 0.1% acetic acid in water and acetonitrile.
In the second part of this study, delta-8-tetrahydrocannabinol (Δ8-THC) and Δ9-THC are baseline separated in an isocratic condition using 0.1% acetic acid in water and acetonitrile. Δ8-THC is an isobaric isomer of Δ9-THC that differs by the position of a double bond. It has lower psychoactive potency, more chemically stable, and potentially better medicinal properties than Δ9-THC.
Cannabinol (CBN) is used to monitor the freshness of the sample since Δ9-THC easily oxidizes to CBN. Cannabidiol (CBD) has no psychoactive activity but it has many potent medicinal properties.
These four cannabinoids, CBD, CBN, Δ9-THC, and Δ8-THC were analyzed by reversed-phase core-shell HPLC columns. The C18 core-shell column produced co-eluting peak of Δ9-THC and Δ8-THC. The peak shapes in this column were fronting under the MS-friendly experimental condition.
Cosmocore Cholester is a core-shell HPLC column that has similar hydrophobicity as C18. The rigid cholesterol functional group provides it with higher steric selectivity to resolve Δ9-THC and Δ8-THC peaks. The peak shapes were symmetrical using MS-compatible solvents as the mobile phase.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | yes | Nacalai USA |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | yes |